Zymeworks Inc. (ZYME) stock
Close on Nov 11, 2026Market cap $2.06BP/E 55.9Yield –
Zymeworks Inc. grew revenue 97.8% to $265.97M over the twelve months to Sep 30, 2026. Free cash flow was -$112.83M. At the latest close the market valued the company at $2.06B, 55.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.06B
- P/E ratio
- 55.9
- Price to sales
- 7.76
- Price to book
- 7.99
- Dividend yield
- –
- Free cash flow yield
- -5.47%
Fundamentals
- Revenue
- $265.97M
- Net income
- $43.31M
- EPS, diluted
- $0.52
- Free cash flow
- -$112.83M
- Book value per share
- $3.39
- Diluted shares
- 76M
Trading
- Next earnings
- Mar 1, 2027 (estimated, before the open)
- Previous close
- $31.46
- Open
- $31.80
- Day's range
- $28.92 – $31.94
- Volume
- 980,378
- Average volume (20 days)
- 1,347,010
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 0.85
- 52-week range
- $18.20 – $31.97
- RSI (14 days)
- 52.8
- Volatility (1 year)
- 54.1%
- Relative volume
- 1.11×
- WACC
- 9.1%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZYME | S&P 500 | Difference | ZYME per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.7% | -2.4% | +15.1 pts | ||
| 3 months | +19.5% | -1.2% | +20.7 pts | ||
| Year to date | +10.4% | +12.3% | −1.9 pts | ||
| 1 year | +47.7% | +12.4% | +35.3 pts | ||
| 3 years | +298.8% | +78.8% | +220.0 pts | +58.6% | +21.4% |
| 5 years | +46.4% | +75.2% | −28.7 pts | +7.9% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zymeworks filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
About Zymeworks
Pharmaceutical Preparations
Zymeworks is a global biotechnology company focused on discovering, developing, and commercializing novel biotherapeutics for difficult-to-treat diseases, with a primary focus on oncology, inflammation, and autoimmune disorders. The company’s pipeline includes antibody-drug conjugates (ADCs) and multispecific antibody therapeutics (MSATs) engineered using proprietary technology platforms such as Azymetric, EFECT, and ProTECT. Its lead asset, zanidatamab (marketed as Ziihera), has received regulatory approval for treating HER2-positive biliary tract cancer, alongside earlier-stage candidates including pasritamig, ZW191, ZW251, ZW220, ZW209, and ZW1528. Rather than commercializing all programs independently, the company licenses assets and enters into strategic risk-sharing collaborations with biopharmaceutical partners, including Jazz Pharmaceuticals, BeOne Medicines, and Johnson & Johnson.
Company profile, executives and historyZymeworks stock: common questions
What is Zymeworks's stock price?
ZYME closed at $29.07 on Nov 11, 2026, down 7.60% on the day. Over the past 52 weeks it traded between $18.20 and $31.97.
What is Zymeworks's market cap?
Zymeworks was worth $2.06B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ZYME's P/E ratio?
ZYME trades at 55.9 times earnings, based on diluted earnings per share of $0.52 over the twelve months to Sep 30, 2026.
How much revenue does Zymeworks make?
Zymeworks reported revenue of $265.97M for the twelve months to Sep 30, 2026, up 97.8% from a year earlier.
Does Zymeworks pay a dividend?
No. Zymeworks has not paid a cash dividend over the last twelve months.
When does Zymeworks report earnings next?
Zymeworks is expected to report Q4 FY2026 results on Mar 1, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ZYME stock performed over the past year?
Including dividends, ZYME returned +47.7% over the past year, against +12.4% for the S&P 500.
How many ZYME shares are sold short?
6M shares were sold short at the latest FINRA report, 20.29% of the float, or 4.3 days of average trading volume.
Who are Zymeworks's competitors?
Companies most similar to Zymeworks by business, industry and size include XNCR, FHTX, ADCT, NKTR, XLO.
See a number that looks wrong?